LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), today announced the closing of its previously announced $7 million financing. As of April 30, 2025, ...
TNF new strategic partner LightSolver named a 2025 World Economic Forum Technology Pioneer and recognized in Gartner’s 2025 Hype Cycle for Data Center Infrastructure Technologies PharmaCyte Biotech ...
・The stake sale comes on the heels of the company increasing its stake in TNF Pharmaceuticals in September by an additional $3 million. ・PharmaCyte said that it plans to continue pursuing ...
PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), today announced the successful monetization of its stake in Femasys Inc. (NASDAQ: FEMY), further validating the Company’s ...
- Additional financing supports the advancement of Femasys’ lead product candidate, FemBloc ® for permanent birth control, to initial clinical data readout - ATLANTA, Nov. 15, 2023 (GLOBE NEWSWIRE) -- ...
LAS VEGAS--(BUSINESS WIRE)-- PharmaCyte Biotech, Inc. (PMCB) (“PharmaCyte” or the “Company”) announced today that it has entered into a securities purchase agreement for a $7.0 million financing with ...
PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results